Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
12.11B
Market cap12.11B
Price-Earnings ratio
15.96
Price-Earnings ratio15.96
Dividend yield
Dividend yield
Average volume
3.08M
Average volume3.08M
High today
$48.17
High today$48.17
Low today
$46.13
Low today$46.13
Open price
$46.57
Open price$46.57
Volume
2.18M
Volume2.18M
52 Week high
$49.62
52 Week high$49.62
52 Week low
$33.76
52 Week low$33.76

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $48.16. The company's market cap stands at 12.11B, with a P/E ratio of 15.96.

On 2026-05-11, Exelixis(EXEL) stock traded between a low of $46.13 and a high of $48.17. Shares are currently priced at $48.16, which is +4.4% above the low and -0.0% below the high.

The Exelixis(EXEL)'s current trading volume is 2.18M, compared to an average daily volume of 3.08M.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $49.62 and a 52-week low of $33.76.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $49.62 and a 52-week low of $33.76.

EXEL News

Simply Wall St 2d
A Look At Exelixis Valuation After Strong Q1 2026 Results And Zanzalintinib FDA Milestone

Advertisement Why Exelixis stock is on investors’ radar after Q1 2026 Exelixis (EXEL) is back in focus after first quarter 2026 earnings, with revenue of US$6...

A Look At Exelixis Valuation After Strong Q1 2026 Results And Zanzalintinib FDA Milestone
TipRanks 4d
Exelixis price target raised to $50 from $49 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $50 from $49 and keeps an Equal Weight rating on the shares after the company shared updates...

TipRanks 5d
Exelixis Kept at Hold as Cabo Momentum Offsets Pipeline Uncertainty; Price Target Raised from $49 to $50

In a report released today, Sean Laaman from Morgan Stanley maintained a Hold rating on Exelixis, with a price target of $50.00. Claim 55% Off TipRanks Unlock h...

Analyst ratings

48%

of 21 ratings
Buy
47.6%
Hold
47.6%
Sell
4.8%

More EXEL News

Simply Wall St 5d
Margin Gains From Oncology Portfolio Might Change The Case For Investing In Exelixis

Exelixis, Inc. has reported first-quarter 2026 results, with revenue of US$610.81 million and net income of US$210.47 million, alongside higher basic and dilute...

Margin Gains From Oncology Portfolio Might Change The Case For Investing In Exelixis
Nasdaq 5d
Exelixis, Inc. Reports Climb In Q1 Profit

(RTTNews) - Exelixis, Inc. (EXEL) revealed earnings for its first quarter that Increases, from last year The company's bottom line totaled $210.47 million, or...

Exelixis, Inc. Reports Climb In Q1 Profit
Nasdaq 5d
Exelixis Q1 2026 Earnings Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Exelixis Q1 2026 Earnings Transcript
TipRanks 6d
Exelixis Posts Strong Q1 Results, Expands Share Buybacks

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.